(19 May 2020) A world’s leading biotechnology company, Amgen Korea (General Manager: Sang Noh) announced on 19 May the donation to the Korean Red Cross (KRC) and Seoul Council on Social Welfare (SCSW) to help address the novel coronavirus disease (COVID-19) crisis.
The contribution shows Amgen Korea’s commitment to playing its part in the fight against COVID-19 to help vulnerable groups who are left in a welfare blind spot. The funds will be put to use to provide much-needed help for public health care supports and emergency livelihood support for the vulnerable via the KRC and SCSW.
It is part of Amgen’s response at the corporate headquarters level to the global COVID-19 crisis. The company spares no effort to help the local communities through this difficult time by supporting patient-focused organizations and relief groups and to protect patients and its employees all over the world. It also provides free access to online learning programs co-developed by the Amgen Foundation and Harvard University, including LabXchange and Khan Academy, for teachers and students to continue their science education during school closures.
Kyung-seo Park, President, KRC said: ““I would like to thank all Amgen Korea employees who have constant attention to the local community and continue to engage in social contribution activities. We will continue to work hard to help and support people in all walks of life affected by COVID-19.”
Hyun-hun Kim, Chairman, SCSW said: “The funds from Amgen Korea will be directed to support vulnerable seniors in Seoul affected by COVID-19, and to address urgent needs quickly. We will always do everything we can for those who often go unnoticed in our communities to make sure their suffering is not exacerbated by COVID-19.”
Sang Noh, General Manager, Amgen Korea, said: “We are proud to be able to support vulnerable seniors who have been hit hard by the ongoing spread of COVID-19. Amgen remains committed to corporate social responsibilities as a member of our community. Our mission of serving patients is at the heart of everything Amgen does as the company unfolds various relief efforts to protect the health and safety of patients and our employees all over the world. Amgen Korea too will do our part in emergency response efforts to the COVID-19 crisis in Korea by our communities and the government.”
In the fight against COVID-19, Amgen and the Amgen Foundation committed up to 12.5 million dollars (appr. 15.5 billion won) directed to support local emergency response efforts in America and international communities in March. In addition, Amgen leverages its strong presence in biotechnology to develop a therapeutic to treat COVID-19. It recently announced strategic partnership with Adaptive Biotechnologies to discover and develop neutralizing antibodies to prevent or treat COVID-19, and contributes scientific insights with deCODE Genetics, a subsidiary of Amgen who is conducting demographic analyses aimed at helping address the COVID-19 pandemic.
# # #
This media release was prepared to provide information on Amgen’s general business activities. Please take care not to risk potential violation of laws and regulations related to pharmaceutical advertising when referring to information contained in the media release.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
About Amgen Korea
Amgen Korea was established in November 2015 to further develop Amgen’s clinical pipeline which offers a wide range of products for bone disease, cardiovascular, oncology/hematology, nephrology, inflammation, neuroscience treatment and biosimilars, as well as to provide innovative medicines to patients in Korea who are suffering from severe diseases. As a member of the biotechnical industry, Amgen Korea will continue to contribute to the development of the Korean pharmaceutical industry by carrying forward diversified and positive activities.
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation.
We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
Min-Jung Jung (firstname.lastname@example.org)
Jina Lee (email@example.com)